Alcohol
Volume 27, Issue 1 , Pages 7-11 , May 2002

Liver disease in alcohol abusers: clinical perspective

  • Anna Mae Diehl

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-410-955-7316; fax: +1-410-955-9677.(A.M. Diehl)

Received 23 November 2001 ,Accepted 20 December 2001.

References 

  1. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis (a double-blind, placebo-controlled trial). Gastroenterology. 2000;119:1637–1648
  2. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110:658–690
  3. Galambos JT. Natural history of alcoholic hepatitis. 3. Histological changes. Gastroenterology. 1972;63:1026–1035
  4. Gao W, Connor HD, Lemasters JJ, Mason RP, Thurman RG. Primary nonfunction of fatty livers produced by alcohol is associated with a new, antioxidant-insensitive free radical species. Transplantation. 1995;59:674–679
  5. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis (natural history and prognostic factors). Hepatology. 1987;7:122–128
  6. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990;113:299–307
  7. Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo R, Gent M, Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med. 1988;318:1709–1713
  8. Levi AJ, Chalmers DM. Recognition of alcoholic liver disease in a district general hospital. Gut. 1978;19:521–525
  9. MacSween RNM, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis. 1986;6:221–232
  10. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993;13:170–182
  11. Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol. 1994;2:335–343
  12. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–111
  13. Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med. 1987;317:1421–1427
  14. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2:33–42
  15. Poupon RY, Serfaty LD, Amorim M, Galulal G, Chretien Y, Chazouilleres O. Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology. 1999;30:406A
  16. Schenker S, Perkins HS, Sorrell MF. Should patients with end-stage alcoholic liver disease have a new liver?. Hepatology. 1990;11:314–319
  17. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. Ann Intern Med. 1986;104:399–404

☆ Editor: T.R. Jerrells

PII: S0741-8329(02)00204-5

Alcohol
Volume 27, Issue 1 , Pages 7-11 , May 2002

Article Tools